Orphalan Initiates Global Phase 3 TRADITiONAL Study of Investigational Once-Daily Trientine Therapy in Wilson Disease

Phase 3trientine tetrahydrochlorideD-penicillaminePositive

AI Analysis

Summary

Orphalan Inc. announced the initiation of the global Phase 3 TRADITiONAL study evaluating an investigational once-daily trientine tetrahydrochloride formulation compared to D-penicillamine as first-line treatment for Wilson disease.

Clinical Trial Data

Phase

Importance:6/10

Sentiment:

0.30

Phase 3trial initiationrare diseaseWilson diseasetrientineonce-daily formulation

Related Companies

$GBCYD $TRAX

Read the original article

Published by PR Newswire Pharma on September 8, 2026 1:00 PM

Read Original